STMN1 and proximal spinal muscular atrophy: Recently, in vitro studies on iPSCs-derived MNs showed efficacy of several compounds (some of them already used to treat ALS or epilepsy) in rescuing both mitochondrial dysfunctions and SMA phenotypes—with or without increasing SMN protein levels—adding new promising candidates for a therapy [74,76,85,109].